OR52 Ides desensitization therapy: Breaking down antibody barriers to transplantation

Despite increased transplant rates for highly sensitized candidates, inequities for those with CPRA u003e 99.7% remain. This case highlights the efficacy of an endopeptidase (IdeS) to cleave IgG HLA-specific antibodies and complications for donor-specific HLA antibody (DSA) monitoring in the presence of therapeutic agents. DSA was evaluated using flow cytometric crossmatch tests (Flow-XM) and Luminex immunoassays (Lifecodes classes I and II single antigen; Immucor-Lifecodes, Stamford, CT and Single Antigen Beads; One Lambda, Canoga Park, CA). Sera were pretreated using Melon Columns™. A 43 year old male with a CPRA of 99.99% was entered into a clinical trial investigating the efficacy of IdeS to cleave IgG molecules and render them ineffective in eliciting complement activation or antibody-dependent cellular cytotoxicity. A deceased donor was identified to whom the patient had HLA-DP DSA yielding a positive prospective Flow-XM. Within 2 h of IdeS administration, immunoassays and a Flow-XM revealed no detectable DSA. Due to concern for DSA rebound, alternate day DSA monitoring and intense post-transplant immunosuppression were employed. Two single antigen panels confirmed DSA reappearance on POD7 prior to high dose immunoglobulin (IVIG) dosing. Administration of IVIG produced an increase in the negative and positive control beads and reactivity with self HLA-antigens (3400 mean fluorescent intensity, MFI). Utilization of multiple bead assays, Flow-XM tests, and HLA pattern analysis rather than MFI was needed to monitor further increases in DSA that would prompt therapeutic plasmapheresis (TPE). Cumulative DSA test analysis revealed a stabilization of DSA accompanied by declining serum creatinine values with no initiation of TPE. New therapeutics hold promise for removing DSA barriers; however, post transplant monitoring can be challenging due to test interference that accompany these biologics. This case illustrates the use of multiple assays and HLA pattern analysis to guide post transplant care. Download high-res image (270KB) Download full-size image A.M. Jackson: 3. Speaker’s Bureau; Company/Organization; Thermo Fisher Scientific .